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This review focuses on a specific interaction occurring between the nicotinic cholinergic
receptors (nAChRs) and the glutamatergic receptors (GluRs) at the nerve endings level.
We have employed synaptosomes in superfusion and supplemented and integrated
our findings with data obtained using techniques from molecular biology and immuno-
cytochemistry, and the assessment of receptor trafficking. In particular, we characterize
the following: (1) the direct and unequivocal localization of native a-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid (AMPA) and N-methyl--aspartate (NMDA) gluta-
matergic receptors on specific nerve terminals, (2) their pharmacological characterization
and functional co-localization with nAChRs on the same nerve endings, and (3) the
existence of synergistic or antagonistic interactions among them. Indeed, in the rat
nucleus accumbens (NAc), the function of some AMPA and NMDA receptors present
on the dopaminergic and glutamatergic nerve terminals can be regulated negatively or
positively in response to a brief activation of nAChRs. This effect occurs rapidly and
involves the trafficking of AMPA and NMDA receptors. The event takes place also at
very low concentrations of nicotine and involves the activation of several nAChRs sub-
types. This dynamic control by cholinergic nicotinic system of glutamatergic NMDA and
AMPA receptors might therefore represent an important neuronal presynaptic adaptation
associated with nicotine administration. The understanding of the role of these nicotine-
induced functional changes might open new and interesting perspectives both in terms
of explaining the mechanisms that underlie some of the effects of nicotine addiction and
in the development of new drugs for smoking cessation.
Keywords: nicotinic receptors, AMPA receptors, NMDA receptors, synaptosomes, neurotransmitter release,
receptor–receptor interactions, synaptic plasticity
Introduction
Neuronal nicotinic receptors (nAChRs) are widely distributed in the rats’ central nervous system
(CNS). They are located on different types of neurons, and are thought to serve different functions
(Dajas-Bailador and Wonnacott, 2004). Accordingly, the outcome of the nAChRs stimulation
depends on both the location of the cholinergic neurons and the specific type of neuron on which
Abbreviations: AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; CNS, central nervous system; DA,
dopamine; GABA, g-aminobutyric acid; GluN2B/GluN2A, Glutamate N2B/N2A subunits; NAc, nucleus accumbens;
nAChR, nicotinic acetylcholine receptor; NMDA, N-methyl--aspartate; NMDARs, NMDA receptors.
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the receptors are expressed. Data from studies performed
with genetically modified mice combined with neurotransmit-
ter release and electrophysiological data consistently show that
nAChRs exert a predominant role in themodulation of the release
of neurotransmitters in the brain (Wonnacott, 1997).
Certainly, one of the most studied roles of nAChRs present on
nerve endings is their ability to facilitate the release of several
neurotransmitters (Arqueros et al., 1978; Wonnacott, 1997; Sher
et al., 2004; Jones and Wonnacott, 2005; Marchi and Grilli, 2010).
The effect of nicotine occurs throughout the activation of nAChR
subtypes, which have different pharmacological and functional
characteristics. One of the most abundant nAChRs present in
the CNS, the a4b2 nAChR subtype, favors the entry of sodium
and causes the depolarization that in turn activates the voltage
operated calcium channels and thus facilitates the entry of calcium
(Wonnacott, 1997; Dajas-Bailador andWonnacott, 2004). Others,
such as the a7 nAChR subtypes, are muchmore permeable to cal-
cium (Bertrand et al., 1990) which when present in the cytoplasm-
may activate the mobilization of calcium from intracellular stores
(Dickinson et al., 2008). Throughout both of these mechanisms,
nicotine evokes the release of several neurotransmitters (Turner,
2004; Zappettini et al., 2010). The EC50 value of nicotine falls
within a micromolar range (McGehee and Role, 1995; Vibat et al.,
1995; Buisson et al., 1996), while at concentrations equal to or less
than 0.1mMnicotine is really little or non-effective (Marchi et al.,
2002; Zappettini et al., 2011).
However, quite interestingly, nicotine, may also modulate the
functional responses of some receptors co-existing with nAChRs
on the same nerve ending (Vizi and Lendvai, 1999; Sher et al.,
2004; Parodi et al., 2006; Patti et al., 2006; Grilli et al., 2008,
2009a,b; Lin et al., 2010; Marchi and Grilli, 2010). This ability of
nicotine in controlling receptor-mediated responses is relatively
new and particularly intriguing when considering that some-
times it occurs also at nicotine concentrations insufficient to
elicit neurotransmitter release. Briefly, the mechanism of recep-
tor–receptor cross talk escapes that of control of neurotransmitter
exocytosis but it finely tunes those mechanisms controlling in-out
movements of receptors in synaptosomal plasma membranes. In
particular, at the level of dopaminergic terminals, nicotine may
exert a negative modulatory effect on the functionality of other
receptors, coexistingwith nAChRs, and this gives rise to a decrease
of dopamine (DA) release if elicited by other neurotransmitter sys-
tems. Accordingly, nicotine used at low concentrations does not
produce its typical stimulatory effect onDA release but conversely
may cause inhibitory effects..
The modifications of receptor function sometimes are the out-
come of a direct structural interaction between the two receptor
systems involved, or are due to indirect effects mediated by a
chain of events leading to this result. The most common mech-
anisms which underlie receptors’ modulation relate to changes in
receptor affinity, variations in the ions permeability, and/or in the
transduction signaling pathways, as well as changes in receptor
trafficking. The interaction among co-expressed receptors may
modulate neurotransmission function via several receptor sys-
tems (Raiteri et al., 1992; Pittaluga et al., 2000, 2005; Marchi and
Grilli, 2010; Cong et al., 2011; Musante et al., 2011; Delille et al.,
2013).
It is known that nAChRs coexist with glutamatergic a-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-
methyl--aspartate (NMDA) receptors on several neurons and
particularly at nerve endings level (Marchi and Grilli, 2010;
Marchi et al., 2014; Marks et al., 2014). The present review takes
into account this new aspect of neuronal nicotinic activity with
particular regard to the effects of nicotine on indirect modulation
of glutamate and DA release. Of course, this particular effect of
nicotine that occurs at the level of some presynaptic nerve termi-
nals could even concern receptors present at the postsynaptic level
thus providing a possible broader look at the action of nicotine in
the brain.
Isolated Nerve Terminals in Superfusion:
An in vitro Model for Studying Functional
Interaction between Presynaptic
Receptors
Isolated nerve endings (synaptosomes) are subcellular particles
of functionally active nerve tissue, which can be obtained easily
by means of a special homogenization of brain tissues (Gray
and Whittaker, 1962). These particles can be purified from the
other components of the homogenate by centrifugation in a den-
sity gradient (Nagy and Delgado-Escueta, 1984; Dunkley et al.,
2008). Synaptosomes have been characterized both morpholog-
ically and biochemically (Taupin et al., 1994; Feligioni et al.,
2006). Morphologically, they resemble as small rounded pock-
ets of 1–2 microns in diameter. They retain on the neuronal
membrane structures present in the nerve ending in vivo (i.e.,
receptors, carriers, etc.). Therefore, when incubated in suitable
physiological solutions, synaptosomes are capable of performing
the neurochemical activities characteristic of the nerve terminals
from which they originate. An important point is that synapto-
somes are derived from neurons that were formed, developed,
and differentiated in their natural environment, the living brain,
allowing a reliable analysis of the events that occurs in CNS.
More specifically, the synaptosomes’ neuronal origin as well as
the lack of the neuronal/glial network that usually prime the
physiological plasticity of neurons reduce eventual sources of
bias for downstream analyses. This aspect must be taken into
consideration when using other in vitro experimental models,
such as primary neuronal cultures, which often have glial net-
works still present to improve culture conditions. The use of
the superfusion technique in which synaptosomes are layered
in a monolayer on microporous filters and up-down super-
fused with physiological solutions, has allowed us to overcome
most of the problems associated with studies of neurotransmitter
release with nerve endings in incubation (Raiteri et al., 1974).
Under these experimental conditions, the superfusion medium
removes the neurotransmitters released before they can interact
and activate structures such as receptors or carriers present on
the nerve endings, thereby excluding any possible indirect effects.
Accordingly, under these experimental conditions the targets on
the synaptosomal membranes such as receptors and/or carriers
can be selectively activated by ligands present in the perfusion
medium. Therefore, any effect on the release of a neurotransmitter
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may be attributed exclusively to an action on targets present
on the nerve ending that specifically releases that neurotrans-
mitter. In fact, neurotransmitter release can be triggered not
only by depolarizing substances (KCl, veratrine, etc.), but also
by drugs activating receptors present on the nerve terminals
and which are stimulated by nicotinic and glutamatergic ago-
nists. For all these reasons, this well-known preparation (Gray
and Whittaker, 1962; Raiteri et al., 1974) remains an excellent
model for studying molecular and subcellular mechanisms of
neurotransmission.
Moreover, using synaptosomes in perfusion to study receptors
that modulate the release of neurotransmitters, supplemented and
integrated with data obtained by molecular biology, immuno-
cytochemistry techniques, and by the assessment of receptor traf-
ficking, enables us to obtain novel information. Indeed, we can
provide relevant and specific information such as: (a) the direct
and unequivocal localization of native receptors on the nerve
terminal releasing the neurotransmitter under investigation; (b)
the identification of the receptors function and the characteriza-
tion of their transduction mechanisms; (c) the pharmacological
characterization of these receptors and themechanismof action of
novelmolecules acting on these sites [i.e., evaluation of the affinity
and potency of agonist and antagonist drugs (EC50, IC50, pA2)];
and (d) the co-localization of different receptors on the same
nerve endings and the presence of a synergistic or antagonistic
interactions between them.
This approach can be also used for studying desensitization,
trafficking of receptors, changes in their subunits structures, eval-
uation of positive or negative allosteric drugs, ex vivo assessment
of receptor function after chronic treatment with drugs, changes
in the environment or during development and aging (enriched
environment, stress, etc.), and the neurotransmitters release from
human tissue (Russo et al., 1993; Risso et al., 2004; Grilli et al.,
2005, 2009a,b; Pittaluga et al., 2007; Musante et al., 2008; Summa
et al., 2011;Marchi et al., 2012;Marrocco et al., 2014;Merega et al.,
2014).
Pre-Treatment with Nicotinic Agonists
Modifies the Function of Glutamatergic
NMDA Receptors Present on Nerve
Terminals
The presence of the NMDA receptors (NMDARs) on neuronal
membranes is quite important since it is connected to various
plastic events of the synapse. Although NMDARs are not mobile
like AMPARs, they also migrate from the endoplasmic reticulum
to the membrane like all membrane proteins (Groc and Cho-
quet, 2006; Pittaluga et al., 2007). It is therefore possible that
they also undergo changes with regard to their presence at the
level of neuronal membranes, and this may affect their function
and modulatory activity. Several factors may trigger this receptor
trafficking, including different stimuli derived by activation of
receptors (Pittaluga et al., 2004, 2007; Summa et al., 2011). The
specific interaction between the nicotinic cholinergic systems and
the function of glutamatergic neurotransmission is a remarkable
example.
A short pre-treatment of synaptosomes with nicotine (10 min)
decreased the NMDA-induced DA release from nucleus accum-
bens (NAc) nerve terminals (Figure 1; Salamone et al., 2014).
Since the nicotine pre-treatment failed to modify the 4-
aminopyridine-induced DA overflow, changes in the exocytotic
machinery of release do not account for nicotine-induced mod-
ifications of the NMDARs function (Salamone et al., 2014).
These findings unequivocally demonstrate that both nAChRs
and NMDARs are functionally located on the same nerve termi-
nals where they also elicit calcium-dependent neurotransmitter
release. Notably, results obtained by studying the calcium avail-
ability in individual nerve endings indicate that the pre-treatment
with nicotine produced a significant decrease of the calcium tran-
sients evoked by the activation of NMDARs (Salamone et al.,
2014).
Glutamate N2B subunits (GluN2B) are critical component of
presynaptic NMDARs located on NAc DA nerve endings (Sala-
mone et al., 2014). These subunits can undergo phosphorylation
and their stoichiometry plays an essential role in the regula-
tion of NMDAR channel properties (Akashi et al., 2009; Mur-
phy et al., 2014), leaving open the possibility that the altered
responses of NMDARs might involve either a rearrangement of
subunits assembly or a modification of the phosphorylation of
NMDARs. Alternatively, a change in NMDARs trafficking typ-
ified by a reduction of the number of NMDARs present at the
plasma membrane level of DA nerve endings may also occur.
Interestingly, this latter hypothesis has been clearly favored since
biotinylation studies unveiled a reduced density of GluN2B sub-
units in NAc synaptosomal plasmamembranes following nicotine
pre-treatment (Salamone et al., 2014). Altogether, these findings
demonstrate a functional interaction, within the same individual
dopaminergic terminal, between nAChR and NR2B-containing
NMDARs, through an ability of nicotinic agents to induce endo-
cytosis of these latter receptors (Figure 1; Salamone et al., 2014).
With regard to the possible role of specific subtypes of nAChR
involved in this mechanism, we must remember that differ-
ent nAChR subtypes including a-conotoxin-sensitive (a6b2b3,
a4a6b2b3, a6b2, and a4a6b2) and a-conotoxin- insensitive (a4b2
and a4a5b2) subtypes mediate nicotine-evoked DA release from
striatal synaptosomes (Kaiser et al., 1998; Salminen et al., 2007).
Since the inhibitory effect of nicotine pre-treatment was partially
counteracted by a conotoxin MII, it is likely that nAChRs con-
taining the a6 subunit, which is abundant in the NAc (Exley et al.,
2008; Hendrickson and Tapper, 2014, and references therein) are
also involved. The pre-treatment (10min) with 5IA85380, a a4/a6
nicotine agonist, further confirms this hypothesis. Interestingly,
preclinical evidence supports the importance of mesolimbic a6
containing nAChRs in the nicotine addiction (Exley et al., 2008;
Brunzell, 2012). Conversely, a7-nAChR subtypes do not appear to
be involved in any kind of interactionwith glutamatergic receptors
in NAc DA terminals as heralded also by the absence of effects
after the pre-treatment (10 min) with choline (Salamone et al.,
2014).
However, in other neurotransmitter systems it seems that even
a7-nAChRs might be implicated in a cross-talk between nico-
tinic and glutamatergic receptors. A recent report focusing on
glutamatergic synapses indicated that a7-nAChRs might enhance
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FIGURE 1 | A schematic representation of the consequences of
the pre-treatment with nAChR agonists on the ability of NMDAR
agonists (100 mM NMDA and 1 mM glycine) to evoke release of
dopamine (DA) and glutamate (GLU) from rat nerve terminals
and on the GluN2A and GluN2B NMDARs trafficking. The asterisk
indicates that the receptor subtype includes the presence of other
different subunits in a variable manner in addition to the subunit
specified.
the presynaptic surface expression of NMDARs leading to an
increased glutamate release during early synaptic development
(Lin et al., 2010). Interestingly, the NMDARs modulating gluta-
mate release are apparently different from those modulating the
release of other neurotransmitters in several brain areas (Pittaluga
et al., 2001). It can be therefore suggested that the interaction
between nAChRs and NMDARs could be differently organized
in different types of nerve terminals, possibly depending on the
different nAChRs and NMDARs subtypes involved. In support of
this hypothesis, a pre-treatment (10 min) of NAc glutamatergic
synaptosomes with nicotine or the a 7 agonists choline caused a
significant increase of the NMDA-evoked overflow of [3H] -ASP
while, conversely, the pre-treatment (10 min) of glutamatergic
nerve endings with the a4/a6 nicotinic agonist 5IA85380 was
ineffective (Figure 1; Zappettini et al., 2014).
The possibility that nicotinic and NMDA receptors coexist
and may interact on glutamatergic terminals is not surprising.
Indeed, the presence of a4b2 and a7 AChRs on glutamatergic
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nerve endings is well documented in several brain regions (for
a review, see Vizi and Lendvai, 1999) as well as the presence of
NMDA receptors that modulate the release of glutamate (Luccini
et al., 2007; Zappettini et al., 2010; Musante et al., 2011). The
pharmacological characterization indicates that GluN2A sub-
units participate in the expression of these presynaptic NMDARs
located on glutamatergic nerve endings, which therefore differ
from those containingGluN2B subunits present onNAcDAnerve
terminals (Zappettini et al., 2014). Thus, at least some of these
NMDARs are functionally expressed and co-localized both with
a7 nAChRs with whom they can functionally interact. Further-
more, the pre-treatment with nicotine or choline produced a sig-
nificant increase of the calcium transients evoked by the activation
of NMDARs; this event occurred only in glutamatergic nerve end-
ings (Zappettini et al., 2014). This finding is therefore consistent
with the data summarized above, and supports the hypothesis that
the facilitation of the NMDA-evoked overflow could be due to
an increase of the synaptosomal calcium transients (Zappettini
et al., 2014), yet considering that calcium influx can influence
directly neurotransmitter release. It is also important to recall that
NMDARs coexist also with a4b2 nAChR subtypes in glutamater-
gic terminals, but in this case without any functional interaction
among them (Figure 1; Zappettini et al., 2014). Interestingly,
biotinylation studies have shown an increased density of GluN2A
subunits in synaptosomal plasma membranes following nicotine
and choline pre-treatment but no changes after preincubation
with 5IA85380 (Zappettini et al., 2014). These findings demon-
strate the ability of a7 nicotinic but not of a4b2 agonists, to induce
an increase in the trafficking of GluN2A-containing NMDARs
and consequently an increase of the functional responses.
In conclusion, the nicotine-evoked internalization of NMDARs
present on DA nerve endings appears not to depend upon the
activation of one particular subtype of nAChR, but rather on the
characteristics of the NMDARs coexisting with nAChRs on the
same nerve terminal. Conversely, the increase of the response of
the NMDARs present on the glutamatergic nerve endings after
nicotine pre-treatmentmight depend on two concomitant factors:
(a) the activation of a specific nAChR subtype (a7), and (b) the
coexistence of these receptors with NMDARs which contain the
GluN2A subunit (Figure 1; Salamone et al., 2014; Zappettini et al.,
2014).
Pre-Treatment with Nicotinic Agonists
Modifies the Function of Presynaptic
Glutamatergic AMPA Receptors
Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid are
largely responsible for the rapid post-synaptic response to glu-
tamate, are widely present in the CNS, and are differently dis-
tributed both at the post- and presynaptic level. Accordingly, a
significant percentage of dopaminergic terminals present in the
NAc possess GluA2 receptor subunits as demonstrated by func-
tional and immuno-cytochemistry studies (Grilli et al., 2012). The
AMPARs are highly dynamic in their distribution and can cycle
rapidly among the synaptic membrane and intracellular compart-
ments (Henley, 2003; Pittaluga et al., 2006). As a confirmation of
this mobility, even within the nerve endings, the pre-treatment
(10 min) of NAc synaptosomes with nicotine caused a significant
reduction of the AMPA-evoked overflow of DA from NAc nerve
terminals. Accordingly, the loss of function of AMPARs in nico-
tine pre-treated synaptosomes was accompanied by a decreased
insertion of GluA2 subunit proteins in the presynaptic component
of synaptosomal plasmamembranes in the nicotine-treated nerve
endings (Figure 2; Grilli et al., 2012). Interestingly, the decrease
of the AMPA-induced DA overflow in nicotine-pre-treated NAc
dopaminergic terminals was significantly counteracted in synap-
tosomes containing entrapped pep2-SVKI, a peptide known to
compete for the binding of GluA2 subunit to scaffolding pro-
teins involved in AMPARs internalization. Thus, it is likely that
nicotine pre-treatment could favor the internalization of GluA2-
containing AMPARs located on dopaminergic NAc terminals.
This event, however, seems to occur in a selected population
of nerve terminals, since AMPA-induced releasing effect was
halved, but not abolished, by nicotine (Figure 2; Grilli et al.,
2012).
Interestingly, the nicotine-induced changes to release-
regulating presynaptic AMPARs was not limited to DA terminals,
but could also be observed when studying the AMPA-evoked
release of noradrenaline from hippocampal nerve terminals
(Grilli et al., 2012). However, nicotine-induced adaptation of
AMPARs does not represent a generalized event that occurs in all
nerve endings. Indeed, the pre-treatment of NAc synaptosomes
to nicotine failed to cause significant changes of the AMPA-
evoked overflow of g-aminobutyric acid (GABA) and ACh
from these terminals (Figure 2; Grilli et al., 2012). The most
likely explanation for the selective endocytosis of AMPARs that
modulates DA and NA release can be the presence of similar
cyclothiazide-sensitive AMPA receptors endowed with GluA2
subunits, which are susceptible to the internalization (Pittaluga
et al., 1999, 2006; Ghersi et al., 2003; Grilli et al., 2012). Conversely,
the AMPA receptors controlling acetylcholine and GABA release
are cyclothiazide-insensitive and did not undergo a GRIP/ABP/
PICK1-dependent constitutive trafficking (Pittaluga et al., 1997,
2006).
Due to the very heterogeneous presence of nAChRs on
dopaminergic and noradrenergic nerve endings (Sershen et al.,
1997; Zoli et al., 2002; Kennett et al., 2012; Pistillo et al., 2015,
and references therein), it is very difficult to correlate specific
nAChR subtypes with the internalization of AMPA receptors. In
any case, the involvement of a7 nAChR subtype can be excluded
based on the lack of effect of the specific a7 agonist choline due
to the absence of this nAChR subtype on both dopaminergic and
noradrenergic terminals (Clarke and Reuben, 1996; Kaiser and
Wonnacott, 2000).
Conclusions
As summarized above, studies have shown that in the rat NAc
the function of specific GluRs present on the dopaminergic and
glutamatergic nerve terminals can be negatively or positively reg-
ulated in response to a brief activation of nAChRs (Grilli et al.,
2012; Salamone et al., 2014; Zappettini et al., 2014). The effect
occurs rapidly and seems to be entirely caused by the trafficking
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FIGURE 2 | A schematic representation of the consequences of the
pre-treatment with nAChR agonists on the ability of NMDAR agonists
(100 mM NMDA and 1 mM glycine) to evoke release of dopamine (DA)
and noradrenaline (NA), acetylcholine (ACh) and GABA from rat nerve
terminals and on the GluA2-cyclothiazide sensitive (GluA2 SENS) and
GluA2-cyclothiazide insensitive (GluA2 INSENS) AMPARs trafficking. The
asterisk indicates that the receptor subtype includes the presence of other
different subunits in a variable manner in addition to the subunit specified.
of AMPA and NMDA receptors. However, this takes place only
in certain nerve terminals and after the activation of either a7 or
non-a7 nAChR subtypes. It is quite important to note that these
effects occur at very low concentrations of nicotine (Salamone
et al., 2014). Interestingly, these nicotine levels, which alone are
unable to evoke release of neurotransmitters, are compatible with
the nicotine concentrations present in the venous plasma of heavy
smokers (Benowitz, 1988; for a review, see Matta et al., 2007) or
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even of people under nicotine replacement therapy for smoking
cessation.
Moreover, it is important to note that nicotine at these concen-
trations switches its typical stimulatory effects on DA release into
an inhibitory effect; this phenomenon could be a fine-tuning of
synaptic signals in response to the increased glutamatergic activity
mediated by the upregulation of NR2A-containing NMDARs.
The dynamic control by cholinergic nicotinic system of glu-
tamatergic NMDA and AMPA receptors might therefore repre-
sent an important neuronal adaptation associated with nicotine
administration. If and how this event may have a functional
relevance or may play an important role in the clarification of the
mechanism of action of nicotine may be worth investigating in
the future. Indeed, the understanding of the role of these nicotine-
induced functional changes might open new and interesting per-
spectives in terms of explaining the mechanisms that underlie
some of the effects of nicotine addiction and the development of
new drugs for smoking cessation.
It is rather complicated to contextualize the interaction of these
two neurotransmitter systems mainly because of two reasons: (1)
many neurons are able to interact to each other without mak-
ing synapses. Recently, functional and morphological evidence
has clearly demonstrated that most neurotransmitters can diffuse
once released and achieve distant targets in the CNS, provided
that the target neurons are equipped with receptors (Lendvai
and Vizi, 2008); and (2) nACh, AMPA and NMDA receptors are
located both synaptically and extrasynaptically (Groc et al., 2009,
and references therein; Petralia et al., 2009). In fact, it has been
proposed that GluNR2B-NMDARs are mostly extrasynaptically
while GluNR2A-NMDARs seem to be located mostly at synaptic
level (Groc et al., 2009, and references therein, Petralia et al.,
2009; Sanz-Clemente et al., 2013). Therefore, further investigation
on the interaction of these two neurotransmitter systems at the
nerve terminal level will hopefully shed light on the role that this
mechanism could play both in normal physiology as well as in
nicotine dependence. Of relevance, Pistillo et al. (2015) reviewed
the molecular, functional, and behavioral mechanisms involved
in the nicotine-induced effects in the mesocorticolimbic system,
and discussed the dopaminergic and glutamatergic circuits within
these CNS regions.
The cellular and molecular mechanisms that regulate the pres-
ence of NMDA and AMPA receptors on neurons in the CNS
have been thoroughly investigated over the last decades. There
are several identified mechanisms that can explain the GluRs
trafficking and the consequent impact that these events might
have on the receptors responses (Zhou et al., 2015). NMDAR
surface trafficking is subunit dependent being GluN2A-NMDARs
less mobile and more retained within synapse than GluN2B-
NMDARs. Approximately 30–40% of surface GluN2B-NMDAR
are mobile and the average of synaptic residency time appears to
beminutes (Tovar andWestbrook, 2002; Bard andGroc, 2011, and
references therein).
It has been recently reported that NMDARs may also diffuse
on the surface of neurons in a highly dynamic process (Groc
et al., 2009). The mobility of presynaptic receptors on the neuron
surface might therefore generate different functional responses
(Gomez-Varela and Berg, 2013). How and through the activation
of whichmechanisms nicotine could control the surface dynamics
of GluRs at the nerve terminal levels is at present not easy to
explain. However, although we cannot establish whether the pre-
treatment with nicotine is able to influence the rapid and lateral
redistribution of GluRs at the membrane level, we can reasonable
assume that the changes in the functional response of GluRsmight
to be linked to their trafficking from the cytoplasm to the surface
of the terminal. Additional investigation is needed to clarify which
mechanism(s) regulating the trafficking of AMPA and NMDA
receptors so far reported is/are triggered or inhibited by the pre-
treatment with nicotine. In fact, a physical interaction between a7
nAChR and the GluNR2A- NMDAR has been recently reported
(Li et al., 2013). Therefore, the possibility that the pre-treatment
with a7 agonists might upregulate the a7 nAChR/NMDAR com-
plex and consequently enhance GluNR2A-NMDARs cell surface
expression has to be also considered.
Several lines of evidence in laboratory animals and preclin-
ical studies demonstrate that different glutamatergic receptors
are critically involved in several nicotine-mediated effects (Vizi
and Lendvai, 1999; Laviolette and Van Der Kooy, 2004; Dani
and Bertrand, 2007; Markou, 2008; Timofeeva and Levin, 2011;
Zhong et al., 2014). This dynamic control by cholinergic nicotinic
system of both NMDA and AMPA receptors might therefore be
crucial for many forms of synaptic plasticity including events
linked to nicotine dependence. Moreover, this event should be
also relevant to understand the interplay between nAChRs and
NMDARs in neurodegenerative diseases. Epidemiological studies
have identified a negative correlation between smoking and the
development of neurodegenerative disorders such as Parkinson’s
disease, and in some studies, Alzheimer’s disease (Picciotto and
Zoli, 2008). These findings have been attributed to the ability
of nicotine to act as a neuroprotective agent. Indeed, a certain
number of studies demonstrated that nicotine can protect against
neuronal death in vitro and in vivo (Dajas-Bailador et al., 2000;
Jonnala and Buccafusco, 2001; Quik et al., 2007; Picciotto and
Zoli, 2008; Shimohama, 2009; Akaike et al., 2010; Bordia et al.,
2015). However, it is also very important to recall that several
studies have reported that nicotine is neurotoxic to several neu-
ronal subtypes, including immature neurons (Trauth et al., 2000;
Laudenbach et al., 2002).
Although relevant, our findings are insufficient to support a
strict correlation among these new nicotine-induced plastic mod-
ifications at nerve terminals, and the events that underlie nicotine
addiction as well as nicotine-induced promnesic and neuropro-
tectant actions. Nevertheless, the working hypothesis is promising
and surely deserves future investigation aimed at highlighting the
roles that nicotine /glutamate receptor functional cross talk play
in the mechanism of synaptic plasticity induced by nicotine.
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